Jan. 14 at 5:09 PM
$CMPS $SNDL
$CMPS Q1 2026 pending phase 3 topline imminent for COMP 360.
I wonder why.. "RUMOR: 🇺🇸 President Trump is considering reclassifying psychedelics as a less harmful drug class."
Maybe this is the reason =
"COMPASS or others) is the most direct federal route to enabling prescription access. There's also a separate ongoing petition to reschedule psilocybin broadly, advanced by DEA to HHS review in 2025, but that's independent.
In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism.
https://x.com/coinvo/status/2011336228478533873?s=46
$IBB $BIB $MNMD
